A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.
Genetic science is a game-changer for medication safety and healthcare overall, and Coriell Life Sciences is leading the way in unlocking its full potential through precision medicine.
A test of the Sum-Share statistical method using only summary-level data found 1,734 genetic variations associated with cardiovascular-related conditions when just one had previously been likely
Coriell Life Sciences is rolling out a new tool in the fight against COVID-19: personalized COVID-19 Risk Scores designed to enable safer re-opening and return to work plans (especially given the recent release of the CDC guidelines for re-opening).
Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. Their study uses pharmacogenomics and economic analysis of real-world clinical data.